- Home
- GNS vs ATRA Comparison
GNS vs ATRA Comparison
Compare GNS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- ATRA
- Stock Information
- Founded
- GNS 2002
- ATRA 2012
- Country
- GNS Singapore
- ATRA United States
- Employees
- GNS N/A
- ATRA N/A
- Industry
- GNS Other Consumer Services
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNS Real Estate
- ATRA Health Care
- Exchange
- GNS Nasdaq
- ATRA Nasdaq
- Market Cap
- GNS 72.9M
- ATRA 67.9M
- IPO Year
- GNS 2022
- ATRA 2014
- Fundamental
- Price
- GNS $1.02
- ATRA $12.29
- Analyst Decision
- GNS
- ATRA Strong Buy
- Analyst Count
- GNS 0
- ATRA 3
- Target Price
- GNS N/A
- ATRA $21.00
- AVG Volume (30 Days)
- GNS 4.4M
- ATRA 65.3K
- Earning Date
- GNS 04-30-2025
- ATRA 08-11-2025
- Dividend Yield
- GNS N/A
- ATRA N/A
- EPS Growth
- GNS N/A
- ATRA N/A
- EPS
- GNS N/A
- ATRA 0.56
- Revenue
- GNS $7,912,718.00
- ATRA $188,667,000.00
- Revenue This Year
- GNS $62.23
- ATRA N/A
- Revenue Next Year
- GNS $69.63
- ATRA N/A
- P/E Ratio
- GNS N/A
- ATRA $21.82
- Revenue Growth
- GNS N/A
- ATRA 202.41
- 52 Week Low
- GNS $0.21
- ATRA $5.01
- 52 Week High
- GNS $1.92
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- GNS 49.91
- ATRA 62.30
- Support Level
- GNS $0.81
- ATRA $10.32
- Resistance Level
- GNS $1.08
- ATRA $12.31
- Average True Range (ATR)
- GNS 0.13
- ATRA 0.90
- MACD
- GNS -0.01
- ATRA -0.04
- Stochastic Oscillator
- GNS 51.10
- ATRA 77.93
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).